Carvedilol

Carvedilol is a non-selective beta-blocker: it blocks both the beta-1 receptors, found mainly on the heart, and the beta-2 receptors, found on the blood vessels and the bronchi. To this it adds an alpha-1 receptor antagonist action, which dilates the peripheral vessels. This alpha-1 blockade lowers vascular resistance and reduces afterload, that is, the force against which the heart must eject blood. The dilation of the vessels is not accompanied by the usual reflex tachycardia, because the beta-1 blockade prevents the heart from racing; the effect on heart rate nonetheless remains more moderate than with a purely selective beta-blocker.

Beyond its action on the receptors, carvedilol has antioxidant properties and reduces the formation of oxidized LDL, the form of cholesterol most aggressive toward the artery wall. Its pharmacology is that of a mixture of two enantiomers, two mirror versions of the same molecule: the S(-) form carries most of the beta-blocking activity, while both forms contribute to the alpha blockade. The liver also transforms the molecule into the 4’-hydroxyphenyl metabolite, a hydroxylated derivative about thirteen times more potent than the parent drug at beta blockade. This dual action, on the heart and on the vessels, sets carvedilol apart from conventional beta-blockers.

Carvedilol has three approved indications, all cardiac. The first is heart failure with reduced ejection fraction, that is, when the left ventricle no longer contracts strongly enough to eject a normal volume of blood with each beat. The second is arterial hypertension, where it lowers pressure by relaxing the vessels and slowing the heart. The third is left ventricular dysfunction after a myocardial infarction, in patients whose condition is stabilized.

In heart failure, the value of carvedilol lies in the fact that it protects the failing heart from constant stimulation by adrenaline and noradrenaline, those stress hormones that, over time, exhaust the muscle. By slowing the rate and lowering the workload, it gives the heart time to fill and recover. It is a long-term treatment: the benefit builds over time, and it is not judged on immediate sensation but on the course of the disease and medical follow-up.

Carvedilol is taken with a meal. The presence of food slows its absorption and reduces the frequency of orthostatic effects, those drops in blood pressure that cause dizziness on standing up. There is an immediate-release form, taken twice a day, and a controlled-release form, taken once a day. Treatment always begins at a low dose, on the order of 3.125 to 6.25 mg twice a day, then the dose is increased in gradual steps, which is called titration. This slow increase gives the heart and blood pressure time to adapt.

Regularity is the rule. Oral bioavailability is only about 25%, because a large part of the dose is captured by the liver on first pass, before reaching the circulation; the elimination half-life is between 7 and 10 hours, which explains the dosing schedule. A beta-blocker is never stopped on one’s own and never abruptly: sudden discontinuation exposes the patient to a rebound, with acceleration of the heart and a rise in blood pressure. Any change in dose or discontinuation is decided with the doctor, who will adjust the pace.

In studies on heart failure, compared with a placebo, dizziness affects 32% of people versus 19%, fatigue 24% versus 22%, diarrhea 12% versus 6%, a rise in blood sugar 12% versus 8%, weight gain 10% versus 7%, a slowing of the heart (bradycardia) 9% versus 1%, and a drop in blood pressure 9% versus 3%. In studies on hypertension, where the doses and patient profiles differ, dizziness concerns 6% of patients, bradycardia 2% and orthostatic hypotension 2%. Dizziness and fatigue dominate, especially at the start of treatment and during dose increases.

In people with diabetes, beta-blockers can raise blood sugar and mask the warning signs of hypoglycemia, in particular tachycardia, that rapid heartbeat that usually warns of a blood sugar level that is too low. Without this signal, hypoglycemia can go unnoticed, become severe or persist. This is why blood sugar is part of the monitoring, and why any unusual episode of sweating, confusion or weakness should be reported to the doctor.

Carvedilol is metabolized by the liver, mainly by the CYP2D6 and CYP2C9 enzymes, through oxidation followed by glucuronidation. This pathway explains several interactions. Inhibitors of CYP2D6, such as fluoxetine, paroxetine or quinidine, increase its blood concentrations; rifampicin, conversely, reduces them by about 70%. Amiodarone at least doubles the concentrations of the S(-) form, the most active, with a risk of bradycardia or conduction block; diltiazem and verapamil can also disturb cardiac conduction. Digoxin sees its concentration rise by about 15%, and agents that deplete catecholamines, such as reserpine or MAO inhibitors, expose the patient to severe hypotension and bradycardia. In people with diabetes, adding carvedilol to insulin or oral hypoglycemic agents strengthens their effect.

Monitoring accompanies these effects. Blood pressure and heart rate are measured before initiation and at each dose adjustment; blood sugar is checked, and digoxin is measured when it is co-prescribed, both when carvedilol is introduced and when it is stopped. Certain situations contraindicate the treatment: second- or third-degree atrioventricular block, severe bradycardia, sick sinus syndrome, decompensated heart failure requiring medications that stimulate the heart, active asthma or bronchospasm, and severe hepatic impairment. This framework of monitoring is what allows the dose to be adjusted as precisely as possible, person by person.

Diet does not replace treatment, but it works on the same cardiovascular ground. Magnesium plays a role in heart rhythm and blood pressure regulation, and it is found in abundance in spinach and other leafy green vegetables, almonds, pumpkin seeds, legumes, whole grains and dark chocolate. Vitamin B6 takes part in metabolism, and it is found in bananas, chickpeas, potatoes and fish. Since carvedilol can weigh on blood sugar, a plate rich in fiber and low in fast sugars, with legumes, vegetables and whole grains, supports a more stable sugar metabolism.

Melatonin, the hormone that prepares the body for sleep, exists in tiny amounts in certain foods such as walnuts and grains, but the plate provides only a minuscule fraction of it, nothing like what the body itself produces at night. Fatigue is among the most frequent effects of the treatment, and quality sleep then counts doubly. When a specific need takes shape, for magnesium, vitamin B6 or falling asleep, ordinary food is not always enough to meet it, and that is where a targeted intake makes sense, in addition to your treatment, never in its place.